

# Common Questions About *Clostridium difficile* Infection

BRADFORD T. WINSLOW, MD, *Swedish Family Medicine Residency Program, Littleton, Colorado*

MARY ONYSKO, PharmD, *University of Wyoming School of Pharmacy, Laramie, Wyoming*

KATHLEEN A. THOMPSON, PharmD, *OU Medical Center, Oklahoma City, Oklahoma*

KATHARINE CALDWELL, MD, MPH, *Sea Mar Community Health Center, Everett, Washington*

GORDON H. EHLERS, MD, *Swedish Family Medicine Residency Program, Littleton, Colorado*

*Clostridium difficile* infection is a common cause of antibiotic-associated diarrhea. It causes no symptoms in more than one-half of infected patients, but can also cause a wide spectrum of illnesses and death. The incidence and severity have increased in recent years. The most important modifiable risk factor for *C. difficile* infection is antibiotic exposure; this risk is dose-related and higher with longer courses and combination therapy. *C. difficile* infection is also associated with older age, recent hospitalization, multiple comorbidities, use of gastric acid blockers, inflammatory bowel disease, and immunosuppression. It has become more common in younger, healthier patients in community settings. The most practical testing options are rapid testing with nucleic acid amplification or enzyme immunoassays to detect toxin, or a two-step strategy. Treatment includes discontinuing the contributing antibiotic, if possible. Mild *C. difficile* infection should be treated with oral metronidazole; severe infection should be treated with oral vancomycin. Fidaxomicin may be an effective alternative. Recurrences of the infection should be treated based on severity. Tapering and the pulsed-dose method of oral vancomycin therapy for second recurrences are effective. Prevention includes responsible antibiotic prescribing and vigilant handwashing. Probiotics prevent antibiotic-associated diarrhea, but are not recommended specifically for preventing *C. difficile* infection. (*Am Fam Physician*. 2014;89(6):437-442. Copyright © 2014 American Academy of Family Physicians.)

**CME** This clinical content conforms to AAFP criteria for continuing medical education (CME). See CME Quiz Questions on page 428.

Author disclosure: No relevant financial affiliations.

► **Patient information:** A handout on this topic is available at <http://familydoctor.org/familydoctor/en/diseases-conditions/clostridium-difficile-infection.html>.

**C**lostridium *difficile* is a gram-positive anaerobic bacterium that is transmitted from person to person by the fecal-oral route.

It causes 15% to 25% of cases of antibiotic-associated diarrhea.<sup>1</sup> *C. difficile* infection is defined as at least three unformed stools in 24 hours and a positive stool test for *C. difficile* toxin or endoscopic evidence of pseudomembranous colitis.<sup>2</sup> Overall, 7% to 26% of adults in acute care facilities are colonized with *C. difficile*; more than one-half of these patients are asymptomatic.<sup>2</sup> The risk of colonization increases each day in the hospital, and symptoms usually begin within three days of colonization in symptomatic patients.<sup>2</sup>

The incidence and severity of *C. difficile* infection have increased. In 2005, the incidence in acute care hospitals in the United States was 84 cases per 100,000 persons, more than double the 1996 rate.<sup>3</sup> Mortality rates increased from approximately 0.5 deaths per 100,000 persons in 1999 to approximately 2.0 deaths per 100,000 persons in 2006.

Mortality rates were also higher (6.9% of those infected with *C. difficile*) during a hospital outbreak in Canada.<sup>2,4</sup> The increased incidence and severity are partially due to an epidemic strain, BI/NAP1/027, which produces higher toxin levels and is highly resistant to fluoroquinolones. *C. difficile* infection is most prevalent in hospitalized older persons and debilitated patients, but also affects younger, healthier, community-dwelling patients. A recent study in Minnesota found that 41% of cases of *C. difficile* infection were community acquired.<sup>5</sup>

## Risk Factors

Risk factors for the development of *C. difficile* infection include age older than 64 years, recent hospitalization, antibiotic use, multiple comorbidities, use of gastric acid blockers, previous gastrointestinal surgery, inflammatory bowel disease, and immunosuppression.<sup>6,7</sup> The risk of infection increases by approximately 2% for every year of age greater than 18 years.<sup>8,9</sup> Infection

**SORT: KEY RECOMMENDATIONS FOR PRACTICE**

<i>Clinical recommendation</i>	<i>Evidence rating</i>	<i>References</i>
Testing for <i>Clostridium difficile</i> infection should be performed only once during a single episode of illness because further testing does not improve diagnostic accuracy and may yield false-positive results.	C	12, 13
Vancomycin is the drug of choice for patients with severe <i>C. difficile</i> infection.	C	2, 18
Tapering and the pulsed-dose method of oral vancomycin therapy for second recurrences of <i>C. difficile</i> infection are effective.	C	2, 22
Antimicrobial stewardship programs may reduce the incidence of <i>C. difficile</i> infection.	C	2
Probiotics prevent antibiotic-associated diarrhea, and may reduce <i>C. difficile</i> -associated diarrhea in children and adults younger than 65 years.	B	2, 34-41

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort>.

**HOW IS IT DIAGNOSED?**

The diagnosis of *C. difficile* infection is primarily clinical, although many different tests are available. Clinicians should become familiar with the testing approach used by their laboratory. For a single episode of illness, testing should be performed only once because further testing does not improve diagnostic accuracy and may yield false-positive results.<sup>12,13</sup>

**Evidence Summary**

Many patients are colonized with *C. difficile*, but signs and symptoms occur only when toxin is produced. To reduce false-positive results, appropriate selection of patients for testing is important. One study demonstrated that many patients inappropriately tested for *C. difficile* infection did not have diarrhea or had recently used laxatives.<sup>14</sup>

is uncommon among children, but can occur. Patients with community-acquired *C. difficile* infection are younger, are more likely to be female, have fewer comorbid conditions, are less likely to develop severe infection, and are less likely to have been exposed to antibiotics.<sup>5</sup> Antibiotic exposure is the most important modifiable risk factor. Although even single doses of prophylactic antibiotics can cause *C. difficile* infection, greater number of antimicrobials used, greater number of doses, and longer duration of antibiotic administration increase the risk.

**Diagnosis****WHEN IS TESTING INDICATED?**

Testing for *C. difficile* infection should be considered in patients presenting with at least three unformed stools in 24 hours.

**Evidence Summary**

Patients should be asked about antibiotic use in the past three months, including single perioperative doses. Symptoms vary from mild diarrhea to fulminant colitis, which can be complicated by toxic megacolon, bowel perforation, and sepsis. Less than one-half of patients with *C. difficile* infection have fever, abdominal discomfort, or leukocytosis. Although occult blood may be present in the stool, melena and hematochezia are uncommon.<sup>2</sup> Ileus is a rare presentation of *C. difficile* infection.<sup>10</sup> Guidelines from the American College of Gastroenterology recommend testing all patients with inflammatory bowel disease hospitalized with a disease flare-up.<sup>11</sup>

Enzyme immunoassay is widely used as a rapid test to detect toxins produced by *C. difficile*. Its specificity is high (83% to 98%), but its sensitivity is lower (75% to 95%), because a low level of toxin can lead to false-negative results.<sup>11</sup> Consequently, many institutions have switched to the use of more sensitive and specific nucleic acid amplification testing, which includes polymerase chain reaction, as recommended by the American College of Gastroenterology.<sup>11</sup> Recent studies have shown a significant increase in population-based incidence rates of *C. difficile* infection when laboratories transition from a one-step strategy using enzyme immunoassay to using nucleic acid amplification testing.<sup>15</sup> This approach raises concerns that the increase is due to detection of less severe or subclinical cases, as well as carriers who have diarrhea from other causes. Yet, rapid identification by nucleic acid amplification testing allows for earlier isolation and treatment of patients with *C. difficile* infection, as well as eliminates the need for repeat testing.

An alternative to a one-step approach using nucleic acid amplification testing or enzyme immunoassay is a multistep protocol in which the first step is detection of the glutamate dehydrogenase antigen, which is produced by all *C. difficile* isolates.<sup>16</sup> If this rapid and sensitive test is positive, samples should then undergo analysis to verify toxin production (with one or more of the previously mentioned tests). Further studies are needed to clarify the testing strategy that leads to the most favorable patient outcomes.<sup>11,16,17</sup>

Testing for cure should be avoided in asymptomatic patients because the toxin may be produced after clinical disease has resolved.<sup>2</sup>

**Table 1. Antibiotic Treatment Regimens for *Clostridium difficile* Infection**

Drug	Dosage	Effectiveness	Adverse effects	Cost estimate*	Comments
Metronidazole (Flagyl)	500 mg orally or intravenously three times per day for 10 to 14 days	80%	Nausea, peripheral neuropathy	\$25 (\$340)	For mild infection
Vancomycin	125 mg orally or rectally four times per day for 10 to 14 days	> 90%	Nausea, vomiting; minimal systemic absorption unless severe colonic inflammation	\$800 (NA)	Preferred for severe infection; promotes overgrowth of vancomycin-resistant enterococci
Fidaxomicin (Dificid)	200 mg orally twice per day for 10 days	90%	Nausea, vomiting, abdominal pain	NA (\$3,150)	Narrow spectrum of activity against <i>C. difficile</i> , staphylococci, and enterococci, but negligible activity against gram-negative organisms; minimal systemic absorption

NOTE: Drugs are listed in general order of preference.

NA = not available.

\*—Estimated retail price for a typical course of treatment, based on information obtained at <http://www.goodrx.com> (accessed December 3, 2013). Generic price listed first; brand price listed in parentheses.

Information from reference 19.

## Treatment

### WHAT IS THE BEST APPROACH TO DRUG SELECTION FOR THE FIRST EPISODE?

Treatment includes discontinuing the contributing antibiotic, if it is no longer indicated or an alternative is available. The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America recommend oral metronidazole (Flagyl) for mild cases of *C. difficile* infection. Oral vancomycin is the preferred agent for severe infection.<sup>2,18</sup>

### Evidence Summary

Compared with metronidazole, vancomycin capsules are expensive, but the generic intravenous formulation may be compounded into a less expensive oral solution.<sup>19</sup>

For complicated *C. difficile* infection with ileus, higher dosages of vancomycin (500 mg four times per day) are recommended, although evidence supporting higher dosages is scant.<sup>2</sup> Intravenous metronidazole combined with oral vancomycin may be necessary for severe infection, and vancomycin enemas can also be used.

A randomized, placebo-controlled trial compared oral vancomycin (125 mg four times per day) with oral metronidazole (250 mg four times per day), stratifying patients according to infection severity.<sup>18</sup> Severe infection was defined as meeting two of the following criteria: age older than 60 years, temperature higher than 100.9°F (38.3°C), albumin level less than 2.5 g per dL (25 g per L), or white blood cell count greater than 15,000 per  $\mu$ L ( $15 \times 10^9$  per L) within 48 hours of enrollment. Severe

infection also included endoscopic evidence of pseudo-membranous colitis or intensive care unit treatment. Metronidazole and vancomycin were equally effective for mild infection, whereas vancomycin was superior for severe infection.

Fidaxomicin (Dificid) has a narrow spectrum of activity, which may preserve beneficial gastrointestinal flora, and has high bactericidal activity against *C. difficile*, including the BI/NAP1/027 strain.<sup>20</sup> A randomized trial compared fidaxomicin (200 mg twice per day) with vancomycin (125 mg four times per day) given orally for 10 days.<sup>21</sup> Fidaxomicin was noninferior to vancomycin for clinical cure (88.2% and 89.8%, respectively). Fidaxomicin produced a significantly lower recurrence rate overall (15.4% vs. 25.3%, respectively), although the recurrence rates for the BI/NAP1/027 strain were similar. Fidaxomicin appears to be effective for the treatment of *C. difficile* infection, but more studies are needed to define its role in therapy.

Table 1 provides a comparison of antibiotic regimens for treatment of *C. difficile* infection.<sup>19</sup>

### HOW SHOULD RECURRENT INFECTION BE TREATED?

An initial recurrence should be treated with metronidazole or vancomycin if the recurrent infection is mild, but vancomycin is indicated for severe infection.<sup>18</sup> Tapering and the pulsed-dose method of oral vancomycin therapy for second recurrences are effective.<sup>22</sup> Intestinal microbial transplantation also resolves symptoms in most patients with recurrent infection.

## C. difficile Infection

### Evidence Summary

Overall, 20% to 30% of patients with *C. difficile* infection experience a recurrence of the infection within 60 days. Similar recurrence rates are reported with vancomycin and metronidazole. A second course of either drug for recurrent infection does not increase the risk of an additional episode.<sup>22,23</sup> Metronidazole should not be used for subsequent recurrences because of the risk of neurotoxicity.<sup>2</sup> A typical dosing regimen of oral vancomycin includes 125 mg four times per day for 10 to 14 days, 125 mg two times per day for one week, 125 mg per day for one week, and then 125 mg every two or three days for two to eight weeks.

Toxin binders such as cholestyramine (Questran) bind to vancomycin and metronidazole in the gut, resulting in lower antimicrobial concentrations; they should not be used.<sup>24,25</sup>

Intestinal microbial transplantation, or fecal bacteriotherapy, infuses stool from a healthy donor into the intestinal tract of a patient who has had recurrent *C. difficile* infection. A systematic review found that fecal bacteriotherapy prevented recurrent infection in 92% of 317 patients in 27 case studies.<sup>26</sup> Results varied by technique, and no major adverse events were noted. A follow-up study of 77 patients over an average of 17 months found that 91% achieved resolution of symptoms within 90 days.<sup>27</sup> A randomized trial of 41 patients with at least one relapse found that fecal infusion achieved cure in 81% of patients, compared with 31% in those receiving vancomycin alone and 23% in those receiving vancomycin plus bowel lavage.<sup>28</sup>

### Prevention

#### HOW CAN CLINICIANS ADJUST ANTIBIOTIC USE TO PREVENT C. DIFFICILE INFECTION?

*Minimizing the frequency and duration of antimicrobial therapy and the number of antimicrobial agents prescribed, as well as implementing an antimicrobial stewardship program, are recommended.*<sup>2</sup>

### Evidence Summary

The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America guidelines indicate that restricting cephalosporin and clindamycin use, except for surgical prophylaxis, may prevent *C. difficile* infection.<sup>2</sup>

#### DO HAND HYGIENE AND CONTACT PRECAUTIONS PREVENT C. DIFFICILE INFECTION?

*Handwashing with soap and water or chlorhexidine and barrier precautions should be used routinely in patients with C. difficile infection to prevent transmission.*

### Evidence Summary

Health care workers and visitors who come into contact with persons who have *C. difficile* infection should wash their hands.<sup>2</sup> Handwashing with soap and water is more effective than alcohol-based hand sanitizer and antiseptic wipes, because alcohol does not kill *C. difficile* spores.<sup>2,29,30</sup> Antibacterial soap and chlorhexidine are also effective.<sup>31</sup> Gloves, disposable thermometers, and sporicidal disinfectants should be used.<sup>2</sup> Gown use and isolation of contaminated patients are recommended.<sup>2,32</sup>

Contact precautions should be considered for patients with a history of *C. difficile* infection because skin contamination and shedding can continue for weeks after diarrhea resolves.<sup>33</sup> There are few data regarding the testing and treatment of asymptomatic *C. difficile* infection, but this practice is common.

#### DO PROBIOTICS PREVENT C. DIFFICILE INFECTION?

*The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America do not recommend probiotics to reduce the risk of primary C. difficile infection.<sup>2</sup> However, recent randomized trials and meta-analyses found that probiotics reduced antibiotic-associated diarrhea and may reduce C. difficile-associated diarrhea in children and adults younger than 65 years, both as inpatients and outpatients.<sup>34-40</sup>*

### Evidence Summary

One randomized trial of 135 patients evaluated a probiotic drink containing *Lactobacillus casei*, *Lactobacillus bulgaricus*, and *Streptococcus thermophilus*. After four weeks, none of the patients who took probiotics developed *C. difficile* infection compared with 17% of the patients who took placebo (number needed to treat [NNT] = 6).<sup>34</sup>

Another trial of 255 adults taking antibiotics compared two capsules of a probiotic containing 50 billion colony-forming units of *Lactobacillus acidophilus* plus *L. casei*, one capsule of the probiotic, and placebo.<sup>35</sup> Patients began probiotics or placebo within 36 hours of starting antibiotics and continued until five days after antibiotic cessation. *C. difficile* infection incidence three weeks after completion of the intervention was 1.2% in the high-dose probiotic group (NNT = 4), 9.4% in the low-dose probiotic group (NNT = 7), and 23.8% in the placebo group. No adverse events were noted in either trial.<sup>34,35</sup>

A meta-analysis of 63 randomized controlled trials found a statistically significant reduction in antibiotic-associated diarrhea in patients taking probiotics (NNT = 13).<sup>36</sup> However, this analysis could not determine if probiotics prevented diarrhea specifically caused

**BEST PRACTICES IN INFECTIOUS DISEASE:  
RECOMMENDATIONS FROM THE CHOOSING  
WISELY CAMPAIGN**

Recommendation	Sponsoring organization
Antibiotics should not be used for apparent viral respiratory illnesses (sinusitis, pharyngitis, bronchitis).	American Academy of Pediatrics
Do not use antimicrobials to treat bacteriuria in older adults unless specific urinary tract symptoms are present.	American Geriatrics Society

SOURCE: For supporting citations, see <http://www.aafp.org/afp/cw-table.pdf>. For more information on the Choosing Wisely Campaign, see <http://www.aafp.org/afp/choosingwisely>. To search Choosing Wisely recommendations relevant to primary care, see <http://www.aafp.org/afp/recommendations/search.htm>.

by *C. difficile* infection. Another meta-analysis of 20 randomized controlled trials found that probiotics decreased the risk of *C. difficile*-associated diarrhea by 66% in adults and children. There was no difference between probiotic species used, and trials using multiple species had more robust results compared with those using one species, although both showed statistically significant improvement. Adverse events were less common in the probiotic group than in the group taking placebo.<sup>41</sup>

A third meta-analysis of 84 trials examined the effect of probiotics in preventing many gastrointestinal diseases that included *C. difficile*. A significant benefit of probiotic use occurred in 37% of the studies, whereas 63% of the studies found no benefit to probiotic use. A pooled estimate of the effectiveness of probiotics found a significant 42% risk reduction in the prevention or treatment of gastrointestinal disease. Eight species of probiotics were effective, but no difference was noted between single species and multiple species probiotic formulations. Infants, children, and adults all benefited from therapy, and longer treatment durations (nine to 240 weeks) were more effective than shorter treatment durations (three to four weeks).<sup>37</sup>

A Cochrane review of 23 trials of children and adults, both inpatients and outpatients, taking antibiotics found that probiotics reduced the risk of *C. difficile*-associated diarrhea by 64% (NNT = 29). Probiotics also reduced the risk of developing adverse effects, such as taste disturbance, abdominal cramping, flatulence, nausea, and fever, by 20%. No significant difference in the incidence of *C. difficile* infection was noted.<sup>38</sup> Another Cochrane review of 15 studies evaluated the prevention of antibiotic-associated diarrhea in hospitalized and ambulatory children taking antibiotics. Pooled results showed probiotics reduced the incidence of diarrhea by 48% (NNT = 7 with high probiotic doses). There was significant heterogeneity in probiotic strain, dose, duration, and study quality.<sup>39</sup>

Effectiveness of a high-dose Lactobacilli/Bifidobacteria probiotic formulation in preventing antibiotic-associated diarrhea (including diarrhea caused by *C. difficile*) was assessed in hospitalized adults older than 65 years in a recent randomized, placebo-controlled trial (N = 2,981). The incidence of *C. difficile*-associated diarrhea was lower in the treatment group (0.8% compared with 1.2% in the placebo group); however, this was not statistically significant. Of note, stool samples were not obtained in about 40% of participants because of short duration of diarrhea, which may have missed some cases of *C. difficile* infection.<sup>40</sup>

**Data Sources:** A PubMed search was completed in Clinical Queries using the key terms *Clostridium difficile*; diagnosis; treatment; risk factors; and prevention and control, or tertiary or secondary prevention. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Limits included English-language articles about human subjects. Also searched were the Agency for Healthcare Research and Quality evidence reports, the Cochrane database, Essential Evidence Plus, the Institute for Clinical Systems Improvement, and the National Guideline Clearinghouse database. Search date: December 23, 2013.

### The Authors

BRADFORD T. WINSLOW, MD, FAAFP, is the program director at the Swedish Family Medicine Residency Program in Littleton, Colo., and an assistant professor of family medicine at the University of Colorado School of Medicine in Aurora.

MARY ONYSKO, PharmD, BCPS, is an associate professor of pharmacy practice at the University of Wyoming School of Pharmacy in Laramie.

KATHLEEN A. THOMPSON, PharmD, BCPS, is manager of clinical services at the OU Medical Center in Oklahoma City. At the time this article was written, she was an assistant professor of pharmacy practice at the University of Wyoming School of Pharmacy.

KATHARINE CALDWELL, MD, MPH, is a family physician at the Sea Mar Community Health Center in Everett, Wash. At the time this article was written, she was a third-year resident at the Swedish Family Medicine Residency Program.

GORDON H. EHLERS, MD, is a faculty member at the Swedish Family Medicine Residency Program.

Address correspondence to Bradford T. Winslow, MD, Swedish Family Medicine Residency Program, 191 E. Orchard Rd., Ste. 200, Littleton, CO 80121 (e-mail: [Bradford.winslow@healthonecares.com](mailto:Bradford.winslow@healthonecares.com)). Reprints are not available from the authors.

### REFERENCES

- Centers for Disease Control and Prevention. Frequently asked questions about *Clostridium difficile* for healthcare providers. [http://www.cdc.gov/HAI/organisms/cdiff/Cdiff\\_faqs\\_HCP.html](http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_faqs_HCP.html). Accessed April 16, 2012.
- Cohen SH, Gerding DN, Johnson S, et al.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infect Control Hosp Epidemiol*. 2010;31(5):431-455.

## C. difficile Infection

- Kelly CP, LaMont JT. *Clostridium difficile*—more difficult than ever [published correction appears in *N Engl J Med*. 2010;363(16):1585]. *N Engl J Med*. 2008;359(18):1932-1940.
- Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. *Natl Vital Stat Rep*. 2009;57(14):1-135. [http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57\\_14.pdf](http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_14.pdf). Accessed April 16, 2012.
- Khanna S, Pardi DS, Aronson SL, et al. The epidemiology of community-acquired *Clostridium difficile* infection: a population-based study [published correction appears in *Am J Gastroenterol*. 2012;107(1):150]. *Am J Gastroenterol*. 2012;107(1):89-95.
- Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for *Clostridium difficile* infection and colonization. *N Engl J Med*. 2011;365(18):1693-1703.
- Issa M, Ananthakrishnan AN, Binion DG. *Clostridium difficile* and inflammatory bowel disease. *Inflamm Bowel Dis*. 2008;14(10):1432-1442.
- Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality [published correction appears in *N Engl J Med*. 2006;354(20):2200]. *N Engl J Med*. 2005;353(23):2442-2449.
- Miller M, Gravel D, Mulvey M, et al. Health care-associated *Clostridium difficile* infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. *Clin Infect Dis*. 2010;50(2):194-201.
- Wanahita A, Goldsmith EA, Marino BJ, Musher DM. *Clostridium difficile* infection in patients with unexplained leukocytosis. *Am J Med*. 2003;115(7):543-546.
- Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *Am J Gastroenterol*. 2013;108(4):478-498.
- Deshpande A, Pasupuleti V, Pant C, Hall G, Jain A. Potential value of repeat stool testing for *Clostridium difficile* stool toxin using enzyme immunoassay? *Curr Med Res Opin*. 2010;26(11):2635-2641.
- Aichinger E, Schleck CD, Harmsen WS, Nyre LM, Patel R. Nonutility of repeat laboratory testing for detection of *Clostridium difficile* by use of PCR or enzyme immunoassay. *J Clin Microbiol*. 2008;46(11):3795-3797.
- Dubberke ER, Han Z, Bobo L, et al. Impact of clinical symptoms on interpretation of diagnostic assays for *Clostridium difficile* infections. *J Clin Microbiol*. 2011;49(8):2887-2893.
- Gould VG, Edwards JR, Cohen J, et al. Effective nucleic acid amplification testing on population-based incidence rates of *Clostridium difficile* infection. *Clin Infect Dis*. 2013;57(9):1304-1307.
- Shetty N, Wren MW, Coen PG. The role of glutamate dehydrogenase for the detection of *Clostridium difficile* in faecal samples: a meta-analysis. *J Hosp Infect*. 2011;77(1):1-6.
- Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing *Clostridium difficile*-infection (CDI). *Clin Microbiol Infect*. 2009;15(12):1053-1066.
- Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis*. 2007;45(3):302-307.
- McElhiney LF. Compounding for manufacturer backorders and discontinuations: "Oh no! Not again!" *Int J Pharm Compd*. 2009;13(1):20-25.
- Difidic (fidaxomicin) tablets [package insert]. San Diego, Calif.: Optimer Pharmaceuticals, Inc.; 2013. [http://www.difidic.com/sites/prd-difidic-com.digitalmarketingnext.com/files/prescribing\\_0.pdf](http://www.difidic.com/sites/prd-difidic-com.digitalmarketingnext.com/files/prescribing_0.pdf). Accessed November 5, 2013.
- Louie TJ, Miller MA, Mullane KM, et al.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med*. 2011;364(5):422-431.
- McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent *Clostridium difficile* disease. *Am J Gastroenterol*. 2002;97(7):1769-1775.
- Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of *Clostridium difficile*-associated disease in Quebec, Canada. *Clin Infect Dis*. 2006;42(6):758-764.
- Taylor NS, Bartlett JG. Binding of *Clostridium difficile* cytotoxin and vancomycin by anion-exchange resins. *J Infect Dis*. 1980;141(1):92-97.
- Flagyl (metronidazole) tablets [package insert]. New York, NY: Pfizer; 2013. <http://labeling.pfizer.com/ShowLabeling.aspx?id=570>. Accessed November 5, 2013.
- Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. *Clin Infect Dis*. 2011;53(10):994-1002.
- Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent *Clostridium difficile* infection. *Am J Gastroenterol*. 2012;107(7):1079-1087.
- van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med*. 2013;368(5):407-415.
- Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of *Clostridium difficile*. *Infect Control Hosp Epidemiol*. 2009;30(10):939-944.
- Jabbar U, Leischner J, Kasper D, et al. Effectiveness of alcohol-based hand rubs for removal of *Clostridium difficile* spores from hands. *Infect Control Hosp Epidemiol*. 2010;31(6):565-570.
- Bettin K, Clabots C, Mathie P, Willard K, Gerding DN. Effectiveness of liquid soap vs. chlorhexidine gluconate for the removal of *Clostridium difficile* from bare hands and gloved hands. *Infect Control Hosp Epidemiol*. 1994;15(11):697-702.
- Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated *Clostridium difficile* infection: reviewing the evidence. *Am J Gastroenterol*. 2010;105(11):2327-2339.
- Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of *Clostridium difficile* during and after treatment of *C. difficile* infection. *Infect Control Hosp Epidemiol*. 2010;31(1):21-27.
- Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. *BMJ*. 2007;335(7610):80.
- Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of *Lactobacillus acidophilus* CL1285 and *Lactobacillus casei* LBC80R for antibiotic-associated diarrhea and *Clostridium difficile*-associated diarrhea prophylaxis in adult patients. *Am J Gastroenterol*. 2010;105(7):1636-1641.
- Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA*. 2012;307(18):1959-1969.
- Ritche ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. *PLoS One*. 2012;7(4):e34938. Published online ahead of print April 18, 2012. <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0034938>. Accessed January 23, 2014.
- Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of *Clostridium difficile*-associated diarrhea in adults and children. *Cochrane Database Syst Rev*. 2013;(5):CD006095.
- Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. *Cochrane Database Syst Rev*. 2011;(11):CD004827.
- Allen SJ, Wareham K, Wang D, et al. Lactobacilli and Bifidobacteria in the prevention of antibiotic-associated diarrhoea and *Clostridium difficile* diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 2013;382(9900):1249-1257.
- Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of *Clostridium difficile*-associated diarrhea: A systematic review and meta-analysis. *Ann Intern Med*. 2012;157(12):878-888.